Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C
Article first published online: 16 AUG 2012
© 2012 Blackwell Publishing Ltd
Influenza and Other Respiratory Viruses
Volume 7, Issue 3, pages 456–465, May 2013
How to Cite
Ohfuji, S., Fukushima, W., Tamori, A., Maeda, K., Maeda, A. and Hirota, Y. (2013), Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C. Influenza and Other Respiratory Viruses, 7: 456–465. doi: 10.1111/j.1750-2659.2012.00424.x
- Issue published online: 17 APR 2013
- Article first published online: 16 AUG 2012
- Accepted 27 June 2012; Published Online 16 August 2012.
- 2Incidence of hospital admissions and severe outcomes during the first and second waves of pandemic (H1N1) 2009. CMAJ2010; 182:1981–1987., , , , , .
- 4Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention and control of seasonal influenza with vaccines. MMWR2010; 60:RR-8, PP4.
- 11WHO Global Influenza Surveillance Network. Identification of the haemagglutinin subtype of viral isolates by haemagglutination inhibition testing; in World Health Organization (eds): Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Geneva: World Health Organization, 2011, pp. 43–62.
- 12European Committee for Proprietary Medical Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medical Products, 1997.
- 13Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Bethesda, MD: Food and Drug Administration, 2007.